Camurus

02.05.2017 – 10:06
Camurus and Braeburn Pharmaceuticals Announce Positive Top-line Results from Phase 3 Safety Study of CAM2038
Lund, Sweden and Princeton, New Jersey (ots/PRNewswire) - New data support long-term safety and efficacy of weekly and monthly subcutaneous buprenorphine depots in patients with opioid use disorder Camurus (NASDAQ STO: CAMX) and Braeburn Pharmaceuticals today announced positive top-line results from a long-term ...
mehr
10.09.2013 – 08:02
Camurus Receives Option-exercise Milestone for Octreotide FluidCrystal® Product CAM2029
Lund, Sweden (ots/PRNewswire) - Camurus announced today that Novartis has exercised its option to acquire an exclusive license for the further development and worldwide commercialization of CAM2029 for treatment of patients with acromegaly and neuroendocrine tumors (NETs). The license also covers additional future products based on the Camurus' FluidCrystal(R) ...
mehr